Combined Creatinine-Cystatin C CKD-EPI 2021 Equation:
| From: | To: |
The CKD-EPI 2021 combined creatinine-cystatin C equation estimates glomerular filtration rate (GFR) using both serum creatinine and serum cystatin C biomarkers, along with age and sex. This combined approach provides superior accuracy compared to equations using either biomarker alone.
The calculator uses the CKD-EPI 2021 combined equation:
Where:
Explanation: This equation combines the advantages of both creatinine and cystatin C biomarkers, providing more accurate GFR estimation across diverse populations and clinical scenarios.
Details: Accurate GFR estimation using combined biomarkers is essential for precise diagnosis and staging of chronic kidney disease, particularly in populations where creatinine-based equations may be less reliable.
Tips: Enter serum creatinine in mg/dL, serum cystatin C in mg/L, age in years, and select gender. All values must be valid (creatinine > 0, cystatin C > 0, age between 1-120).
Q1: Why Use Combined Creatinine-Cystatin C Equation?
A: The combined equation provides superior accuracy compared to either biomarker alone, especially in elderly populations, extremes of body composition, and when muscle mass is abnormal.
Q2: What Are The Advantages Over Creatinine-Only Equations?
A: Cystatin C is less affected by muscle mass, diet, and race, making the combined equation more reliable across diverse patient populations.
Q3: When Should Combined Equation Be Used?
A: Recommended when precise GFR estimation is critical, in research settings, for drug dosing decisions, and when creatinine-based estimates are questionable.
Q4: Are There Limitations To This Equation?
A: Requires measurement of both biomarkers, which may increase cost. Less validated in specific populations like pregnant women, amputees, and those with rapidly changing kidney function.
Q5: How Does This Compare To Other Equations?
A: The 2021 CKD-EPI combined equation represents the most recent and accurate method for GFR estimation using commonly available biomarkers.